NCT00132730 arm group 80d0ff954f648c40937f05b834f33ca5 [clinicaltrials_resource:NCT00132730/arm-group/80d0ff954f648c40937f05b834f33ca5]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00132730 arm group 80d0ff954f648c40937f05b834f33ca5 [clinicaltrials_resource:NCT00132730/arm-group/80d0ff954f648c40937f05b834f33ca5]
Bio2RDF identifier
NCT00132730/arm-group/80d0ff954f648c40937f05b834f33ca5
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... d0ff954f648c40937f05b834f33ca5
description [clinicaltrials_vocabulary:description]
Participants receive placebo t ...... 12 weeks in Period III (EXT1)
identifier
clinicaltrials_resource:NCT00132730/arm-group/80d0ff954f648c40937f05b834f33ca5
title
NCT00132730 arm group 80d0ff954f648c40937f05b834f33ca5
@en
type
label
NCT00132730 arm group 80d0ff95 ...... 0ff954f648c40937f05b834f33ca5]
@en